Thanks Sam. Wow blew right through 15K! It's been pretty much a consistent stair step incremental growth. I wonder how much 1A might have had to do with it.
Looks like Vascepa sales increased almost as much as Generic Lovaza sales did.
As long as Vascepa sales quickly get to the point Amarin starts making money instead of losing money, I guess it doesn't matter than Generic Lovaza sales are climbing the same or better rate.
But over time, the Obamacare-favored generic may win out.
Thanks Sam...I didn't see that coming...perhaps the barriers JT mentioned a month ago are taking effect. These could have been some hidden CMS favoring generics over Amarin...despite what the board has previous discussed I know for a fact V scripts have been changed to Generic Omega at the Pharmacy level. (Confidential Source)